|
|
||||||||



*
First Department of Internal Medicine and
First Department of Pathology, Kansai Medical University, Osaka, Japan; and
Department of Animal Development and Physiology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan
| Abstract |
|---|
|
|
|---|

)-producing cells. Here, we
investigate the effects of IFN-
and IFN-
as well as other
cytokines on CD11c+ and CD11c- DC subsets,
directly isolated from the peripheral blood, instead of in
vitro-generated DCs. IFN-
and IFN-
, rather than GM-CSF, were the
most potent cytokines for enhancing the maturation of
CD11c+ DCs. Incubation of CD11c+ DCs with
IFN-
also resulted in increased IL-12 production, and this IL-12
allowed DCs to increase Th1 responses by alloreactive T cells. In
contrast, IFN-
did not induce IL-12 but, rather, augmented IL-10
production. IFN-
-primed matured CD11c+ DCs induced
IL-10-producing regulatory T cells; however, this process was
independent of the DC-derived IL-10. On the other hand, IFN-
by
itself neither matured CD11c- DCs nor altered the
polarization of responding T cells, although this cytokine was a potent
survival factor for CD11c- DCs. Unlike IFN-
, IL-3 was a
potent survival factor and induced the maturation of
CD11c- DCs. The IL-3-primed CD11c- DCs
activated T cells to produce IL-10, IFN-
, and IL-4. Thus,
CD11c+ and CD11c- DC subsets play distinct
roles in the cytokine network, especially their responses to
IFNs. | Introduction |
|---|
|
|
|---|
Type I IFNs (IFN-
) are important cytokines because of their
beneficial use as adjuvant in antiviral or anticancer therapy. Indeed,
in the immune system, type I IFNs have multiple functions, such as
protection of lymphocytes from apoptosis (7), suppression
of cell proliferation (8), up-regulation of MHC class I
molecules (9), and modulation of Ig production (10, 11). Furthermore, type I IFNs share some biological activities
with IL-12, directing Th cells to produce IFN-
, which consequently
inhibits IL-4/IL-5 synthesis (12, 13) and augments NK and
CTL activities (7, 14). Thus, IFN-
could contribute
to innate immunity, activating cytotoxic effector cells and helping to
eliminate microbial agents.
On the other hand, type II IFN (IFN-
) is a product of Th1, CTL type
I (Tc1), and NKT cells and is a major effector molecule in
cell-mediated immunity (15). It has recently been
demonstrated, however, that mouse DCs also produce IFN-
upon
activation, and that IFN-
produced by DCs acts in an autocrine or
paracrine manner to up-regulate DC production of IL-12
(16). Like IFN-
, IFN-
has similar effects on
various cell types, including macrophages and NK cells as well as
lymphocytes. In contrast to IFN-
, however, IFN-
does not
induce MHC class II expression in the mouse and sometimes counteracts
the effects of IFN-
(17).
Therefore, we attempted to clarify the effects of IFN-
and IFN-
as well as other cytokines on the
CD1a+CD11c+ DC subset (as
the major population of myeloid-lineage CD11c+
DCs, hereafter termed CD11c+ DCs) and the
CD1a-CD11c- DC subset
(hereafter termed CD11c- DCs), both of which
were directly purified from the peripheral blood, instead of in
vitro-generated DCs. In this study, we adopted a serum-free condition
for the DC cultures to avoid the effects of serum factors. IFN-
and
IFN-
are potent maturation factors for CD11c+
DCs; IFN-
induces IL-10 production by DCs, whereas IFN-
stimulates IL-12 production. These IFN-
- and IFN-
-primed
CD11c+ DCs evoke preferential production of IL-10
and IFN-
from T cells, respectively. In contrast,
CD11c- DCs do not respond well to IFN-
, but
do survive in the presence of IFN-
or IL-3. IL-3 is a far more
potent maturation factor for CD11c- DCs than
IFN-
in terms of the enhanced expression of MHC and costimulatory
molecules and allows the DCs to induce more Th cells producing IL-10,
IFN-
, and IL-4. Thus, not only do different types of DCs in the
blood have the capacity to induce different Th cell development, but
the same types of DCs can induce different Th cell development
depending on the DC maturation signals.
| Materials and Methods |
|---|
|
|
|---|
Serum-free medium (X-VIVO 20; BioWhittaker, Walkersville, MD)
supplemented with BSA (0.4%) was used throughout the experiments.
Recombinant human cytokines, GM-CSF (50 ng/ml), TNF-
(2.5 ng/ml),
TGF-
1 (1 ng/ml), IL-1
(10 ng/ml), IL-3 (10 ng/ml), IL-4 (50
ng/ml), IL-6 (20 ng/ml), IL-7 (20 ng/ml), and IFN-
(1000 U/ml), were
purchased from Roche (Indianapolis, IN), and IL-2 (100 U/ml), IFN-
2b
(1000 U/ml), IFN-
(1000 U/ml), and soluble CD40 ligand (sCD40L; 1
µg/ml) were obtained from PeproTech (London, U.K.).
Isolation of peripheral blood DCs
Peripheral blood DCs were isolated according to the protocol
previously described (2). Briefly, PBMC were incubated
with anti-CD3 (HIT3a) and anti-CD14 (M5E2) mAbs (both from
PharMingen, San Diego, CA), and cells binding to these mAbs were
removed using sheep anti-mouse Ig-coated magnetic beads (M-450;
Dynal, Oslo, Norway).
CD3-/CD14- cells were
further incubated with CD4-conjugated microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany), and the CD4+ cells
were then enriched through a Mini-MACS magnetic separation column
(Miltenyi Biotec). The resultant DC-enriched population
(CD4+/CD3-/CD14-
cells) was stained with PE-labeled anti-CD11c (Leu M5),
FITC-labeled anti-CD1a (BB-5), PE-cyanin 5.1 (PC5)-labeled HLA-DR
(Immu-357), and a mixture of biotinylated mAbs against lineage markers
(CD3; M2AB, binding to a different determinant from that recognized by
the previous anti-CD3 mAb, CD14; UCHM1, binding to a different
determinant from that recognized by the previous anti-CD14 mAb,
CD16; 3G8 and CD19; HIB19) followed by RED613-streptavidin (Life
Technologies, Gaithersburg, MD). The
CD1a+/CD11c+/lin-/DR+
cells (fraction 1) and
CD1a-/CD11c-/lin-/DR+
cells (fraction 3) were sorted by an EPICS ALTRA flow cytometer
(Coulter, Hialeah, FL). For analyses of the expression of surface
markers, the CD1a+CD11c+ DC
subset was sorted as the
CD1a+/lin-/DR+
fraction without the staining of PE-CD11c (note that all
CD1a+/lin-/DR+
DCs are quite comparable to
CD1a+/CD11c+/lin-/DR+
DCs (Fig. 1
A) when analyzed
after staining with anti-CD11c mAb), and
CD1a-CD11c- cells were
resorted as the CD11c- fraction from the
CD1a-/lin-/DR+
population. The sorted cells were subsequently stained with the
following PE-labeled mAbs: CD121a (IL-1R type 1: clone 6B5), CD25
(IL-2R
: 2A3), CD122 (IL-2R
: TIC-1), CD123 (IL-3R
: 9F5), CD124
(IL-4R
: S456C9), CD125 (IL-5R
: A14), CD126 (IL-6R
: M91),
CD130 (IL-6R
: AM64), CD127 (IL-7R
: R34.34), CD114 (G-CSFR:
LMM471), CD116 (GM-CSFR
: M5D12), CD117 (c-Kit: 95C3), CD135 (FLT-3:
SF1.340), CD131 (common
receptor: 3D7), CD105 (TGF-
1/3R:
N1-3A1), CD119 (IFN-
R
: MMHGR-1), CD120a (TNF-
R p55: 2H10),
CD120b (TNF-
R p75: 4D1B10), and IFN-
R
(MMHAR-2).
|
The sorted DCs were cultured in 96-well flat-bottom tissue
culture plates at 4 x 104 cells in 200 µl
of medium/well. In some cultures UV-irradiated Sendai virus (HVJ,
Cantell strain, provided by Sumitomo Pharmaceuticals, Ehime, Japan) was
added at 5 hemagglutinating units/ml (18). In culture
supernatants of DCs after 24 h, the production of cytokines was
determined by ELISA (kits for IL-12 p70, IL-4, and IL-10 were purchased
from Immunotech (Marseilles, France) and that for IFN-
was
obtained from Endogen (Woburn, MA)).
Cell viability and maturation assays
In the viability assay, viable cells were counted by trypan blue dye exclusion test after the culture and simultaneously evaluated as propidium iodide-negative and annexin V-negative fractions using the annexin V-FITC apoptosis detection kit (Genzyme, Cambridge, MA).
To evaluate cell maturation, the cells were stained with PE-labeled
anti-HLA-DR (L243), HLA-DQ (1a3), CD86 (HA5.2B7), CD80 (MAB104),
CD40 (MAB89), and CD83 mAb (HB15a) and analyzed by a FACScan (Becton
Dickinson, Sunnyvale, CA). In the MLR assay, the cultured DCs (for 1
day) were washed and
-irradiated at 15 Gy, and graded doses of these
cells were then added to 2 x 105 allogeneic
CD4+/CD45RA+ naive T cells
in the medium (RPMI 1640 supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin,
and heat-inactivated 10% FBS (Irvine Scientific, Santa Ana, CA)) for 5
days. The cells were pulsed with 1 µCi of
[3H]TdR during the last 8 h of the culture
period. CD4+/CD45RA+ naive
T cells, negatively selected twice by anti-CD45RO (UCHL-1), -CD8
(T8), -CD14 (M5E2), -CD16 (3G8), -CD19 (HIB19), -HLA-DR (L243), and
-CD11b (ICRF44) mAbs followed by sheep anti-mouse Ig-coated
magnetic beads, were obtained from allogeneic healthy volunteers. The
purity of the cells was 92% or greater by reanalysis using
anti-CD4 and CD45RA mAbs.
Analyses of T cell polarization stimulated by DCs
The sorted DCs precultured with the cytokine for 2 days were
washed and then cocultured with allogeneic
CD4+/CD45RA+ naive T cells
in 96-well flat-bottom tissue culture plates in 200 µl of medium/well
(2 x 104 cultured DCs/2 x
105 T cells). After 6 days of DC-T cell coculture
with or without neutralizing polyclonal Ab to IL-12 (AB-219-NA, 20
µg/ml) or IL-10 (AB-217-NA, 20 µg/ml; both of goat polyclonal IgG
from R&D Systems, Minneapolis, MN), the cells were washed and
subsequently restimulated with PMA (25 ng/ml) and ionomycin (1 µg/ml)
for 8 h. After restimulation, IFN-
, IL-10, and IL-4 in the
culture supernatants were analyzed by ELISA (kit from Immunotech). For
intracellular cytokine analyses, brefeldin A (2 µg/ml) was added to
the cultures for the last 4 h. The cultured cells were stained
with PE-labeled anti-IL-10 (Caltag, Burlingame, CA) plus
FITC-labeled anti-IFN-
(Ancell, Bayport, MN) or with PE-labeled
anti-IL-4 (Becton Dickinson) plus FITC-labeled anti-IFN-
mAbs, using FIX and PERM kit (Caltag), and then were analyzed by a
FACScan.
| Results |
|---|
|
|
|---|
As shown previously, we have identified two dominant populations
of immature DCs (or DC precursors) in peripheral blood based on the
expression of CD1a and CD11c (2):
CD11c+ DC subset
(CD1a+/CD11c+/lin-/DR+)
and CD11c- DC subset
(CD1a-/CD11c-/lin-/DR+;
Fig. 1
A). To analyze the effects of cytokines on the
function of these subsets, we first examined the expression of specific
receptors using mAbs. As shown in Fig. 1
B, both subsets
variably expressed receptors for GM-CSF, IL-3, IFN-
, IFN-
,
TGF-
1, TNF-
(p75), and IL-6. CD11c+ DCs
expressed GM-CSFR at a high level, but IL-3R at a low level, whereas
CD11c- DCs expressed these receptors in a
reciprocal manner. Notably, both subsets, but especially
CD11c- DCs, intensely expressed IFN-
R. The
rest of the receptors were comparably expressed on
CD11c+ and CD11c- DC
subsets. IL-1R type 1, IL-2R
, IL-2R
, IL-4R
, IL-5R
,
IL-6R
, IL-7R
, G-CSFR, c-kit, FLT-3, common
receptor, and
TNF-
R (p55) were expressed weakly or were not detectable on both
subsets (data partially shown in Fig. 1
B).
Effects of cytokines on blood DC survival
We then evaluated the viability of DCs after 1 day of culture in
the presence of a panel of cytokines using the trypan blue dye
exclusion test (Table I
). In the absence
of cytokines, both DC subsets, especially CD11c-
DCs, showed a high mortality because of the spontaneous apoptosis.
GM-CSF, IL-3, IFN-
, and IFN-
variably supported the survival of
both DC subsets. As has been reported, GM-CSF best maintained the
viability of CD11c+ DCs, while IL-3 protected
CD11c- DCs from cell death (3, 19).
Intriguingly, IFN-
and IFN-
substantially enhanced the survival
of CD11c+ DCs, whereas only IFN-
exhibited
this effect on CD11c- DCs.
|
and
IFN-
only maintained viability for 24 h. On the other hand, the
survival of CD11c- DCs was comparably maintained
for 72 h by IL-3 and IFN-
, and the viabilities were not
improved even in the presence of sCD40L, a potent stimulator of DC
maturation.
|
We next examined whether cytokines that maintain DC viability also
induce DC maturation. For CD11c+ DCs, IFN-
and
IFN-
remarkably augmented the expression of MHC class II and
maturation-associated molecules such as CD40, CD80, CD86, and CD83.
GM-CSF only exerted a marginal effect (Fig. 3
). However, IFN-
was slightly more
effective than IFN-
in augmenting the expression of costimulatory
molecules, even though both types of IFNs were comparably efficient for
MHC class II expressions. In contrast to the marginal effects of GM-CSF
on CD11c+ DCs, IL-3 by itself substantially
up-regulated all markers on CD11c- DCs. IFN-
,
however, failed to increase these molecules on
CD11c- DCs. The addition of sCD40L did not
up-regulate the expression of maturation markers when
CD11c- DCs were cultured with IFN-
, but
slightly augmented them when cultured with IL-3.
|
-treated
CD11c+ DCs were more powerful stimulators than
those treated with IFN-
. In line with the changes in phenotype,
GM-CSF only modestly increased DC function (Fig. 4
did not significantly
increase DC function relative to medium alone.
|
We measured the cytokines produced from CD4+
naive T cells that had been stimulated with DC subsets treated with
different cytokines (Fig. 5
). In general,
CD11c+ DCs even precultured with medium alone
preferentially activated T cells to produce Th1 cytokine, i.e., high
amounts of IFN-
and low amounts of IL-10 and IL-4. IFN-
-primed
CD11c+ DCs induced the largest amount of IFN-
,
but did not modulate IL-10 or IL-4 production. In contrast,
IFN-
-primed CD11c+ DCs induced more IL-10 and
less IFN-
without affecting IL-4 secretion, indicating that they
induced the T cell subset phenotypically similar to T regulatory cells
(Tr or Th3 cells).
|
did not modulate T cell responses
compared with the unprimed DCs.
Th1 polarization induced by IFN-
-primed CD11c+
DCs was counteracted by the simultaneous addition of IFN-
. A similar
effect of IFN-
was observed in CD11c- DCs
primed with IL-3.
Cytokine production of each DC subset
To elucidate the priming effect of IFN-
and IFN-
on
CD11c+ DCs and IL-3 on
CD11c- DCs, we analyzed cytokine production from
DCs after stimulation. As shown in Fig. 6
, IFN-
treatment resulted in a marked
up-regulation of IL-12 production, but not IL-10, from
CD11c+ DCs. In contrast, IFN-
was a poor
inducer of IL-12, but dramatically induced IL-10. These findings
indicated that IFN-
and IFN-
reciprocally regulate the IL-12 and
IL-10 production of CD11c+ DCs. No IL-4 was
detectable in supernatants of any of the DC cultures (data not shown),
in agreement with the previous study by Rissoan et al.
(4).
|
after stimulation with Sendai virus (ranging from 3355
to 6006 pg/ml), confirming that CD11c- DCs are
IFN-producing cells. They did not produce IFN-
under any cytokine
stimulations (data not shown).
The effects of the cytokines produced by primed DCs on T cell
polarization were next examined, again by examining the intracellular
cytokine profiles of activated allogeneic T cells in the presence or
the absence of neutralizing Ab to IL-10 and IL-12. Th1 polarization was
demonstrated by CD11c+ DCs that had been
precultured without any cytokines (Fig. 7
A). IFN-
-primed
CD11c+ DCs significantly increased the frequency
of IL-10-producing cells and decreased that of IFN-
-producing cells.
The addition of neutralizing Ab to IL-10 did not change the frequency
of IL-10-producing T cells, but resulted in an increase in
IFN-
-producing T cells (Fig. 7
A). Therefore, the decrease
in the frequency of IFN-
-producing cells, but presumably not the
increase in IL-10-producing cells, relates to the IL-10 secreted from
IFN-
-primed DCs.
|
-primed DCs substantially increased the
number of IFN-
-producing cells, and this was markedly blocked by the
addition of neutralizing Ab against IL-12 (Fig. 7
-primed DCs.
In keeping with the results reported by Cella et al. (5),
CD11c- DCs cultured in the medium alone
activated a substantial number of IFN-
-producing T cells, although
the frequency was far less than that of cultures with
CD11c+ DCs (Fig. 7
B). These activated
T cells, however, produced IL-10. In addition, a small but significant
percentage of T cells were stained with both IL-10 and IFN-
,
indicating that some populations of activated T cells are double
producers of IL-10 and IFN-
. This type of T cell was profoundly
increased in cultures stimulated with IL-3-primed
CD11c- DCs. Furthermore, the number of IL-10
single-producing T cells was also increased. Anti-IL-10-neutralizing
Abs did not influence the induction of IL-10 single- and
double-producing T cells (Fig. 7
B), suggesting that IL-10
does not mediate the induction of IL-10-producing cells. These results
suggest that CD11c- DCs induce Th0 as well as
Th2, and that IL-3 treatment potentiates such activities. To examine
this possibility, T cells were stained with anti-IFN-
and
anti-IL-4 instead of anti-IL-10 Ab. As shown in Fig. 7
C, a significant number of IL-4 single producers and double
producers of IL-4 and IFN-
increased when cultured with IL-3-primed
CD11c- DCs. Therefore, IL-3-primed
CD11c- DCs have the ability to stimulate not
only Th2 but also Th0. On the other hand, IFN-
-primed
CD11c- DCs as well as untreated DCs were
incapable of preferentially inducing either Th2 or Th0, in contrast to
IL-3-primed CD11c- DCs.
Finally, the counteracting effect of IFN-
on the function of
IFN-
-primed CD11c+ DCs or on IL-3-primed
CD11c- DCs was extended to the analyses of
Th-type defined intracellular cytokine expression (Fig. 7
, right
panels).
| Discussion |
|---|
|
|
|---|
and IFN-
were maturation-inducing factors
rather than survival factors even though they maintain
CD11c+ DCs for 1 day (Figs. 2
, but not IFN-
, sustained the
viability of CD11c- DCs for at least 3 days
(Table I
did not act as a maturation-inducing factor on
CD11c- DCs, whereas IL-3 did. Moreover, sCD40L
was ineffective in inducing CD11c- DC maturation
in the presence of IFN-
(Fig. 3
, which is produced in large quantities from
CD11c- DCs upon infection with Sendai virus (our
unpublished observation and reported previously by others (5, 6)), acts as a regulatory factor on
CD11c- DCs to inhibit their maturation. This was
also confirmed in the experiment with allogeneic MLR (Fig. 4
McRae et al. (20) recently reported that IFN-
inhibit the differentiation of monocyte-derived DCs when IFNs are added
at the time of culture initiation of CD14+ cells
with GM-CSF plus IL-4. On the other hand, not only IFN-
but also
IFN-
have been demonstrated to induce final maturation of in
vitro generated DCs (21, 22), which is consistent with our
results. The major findings of this study are 1) that both types of
IFNs induced CD11c+ DC maturation, and 2) that
IFN-
augmented the ability to induce Th1 response, whereas IFN-
stimulated an IL-10-producing Tr response along with the concomitant
inhibition of IFN-
-producing Th1 cell development (Fig. 5
).
The question raised here is how CD11c+ DCs
treated with these two types of IFNs induced different polarized T cell
responses. One possibility is that the skewed T cell responses are due
to the expression level of costimulatory molecules on the DCs, since
DCs stimulated with IFN-
expressed a slightly higher level of
costimulatory molecules on the surface than those stimulated with
IFN-
(Fig. 3
). This seems to relate to the difference in the
magnitude of allogeneic T cell response induced by IFN-
-- or
IFN-
-stimulated DCs (Fig. 4
). The other possibility is that
IFN-
and IFN-
regulate the ability of
CD11c+ DCs to produce different sets of
cytokines. Indeed, this is also the case in our experiments. IFN-
induced a large amount of IL-12p70 production, whereas IFN-
induced
IL-10 production rather than IL-12 p70 (Fig. 6
). Preferential
activation of Th1 by IFN-
-primed CD11c+ DCs
was shown to be mainly due to the DC-derived IL-12 because of the
considerable blocking by the addition of anti-IL-12-neutralizing
Ab, while IL-10-producing Tr cell development was independent of
DC-derived IL-10 (Fig. 7
A). However, the negative regulation
of Th1 development by IFN-
-primed CD11c+ DCs
was shown to be dependent on IL-10, probably either from the DCs or the
developing Tr cells, in agreement with the established idea that IL-10
is capable of inhibiting Th1 development (23, 24, 25). We also
noted that a low, but significant, number of T cells produced both
IFN-
and IL-10 upon culture with IFN-
-primed, but not
IFN-
-primed, CD11c+ DCs. Therefore, IFN-
may induce the production of undetermined cytokines from or surface
molecules on CD11c+ DCs, which would then
actively facilitate IL-10-producing Tr cell development.
As for CD11c- DCs, IL-3 was a sole and effective
maturation-inducing factor in terms of the expression of surface
molecules involved in T cell activation. Eventually, IL-3-primed
CD11c- DCs were capable of inducing a
substantial allogeneic T cell response. However, no cytokine activity,
such as IL-12 and IL-10, was detectable in the culture supernatant.
Kadowaki et al. (26) have reported that pDC2 pretreated
with IL-3 tend to induce Th2 and that a remarkable increase in Th2
cytokines, especially IL-10, is detected, as in our study (Fig. 5
).
This is consistent with the increase in the number of IL-10- and
IL-4-producing cells (Fig. 7
, B and C). In
addition, the frequency of cells producing both IL-10 and IFN-
was
higher than that of cells producing either IL-4 or IL-10 alone. Such
IFN-
producer cells were also found to produce IL-4, indicating that
IL-3-primed CD11c- DCs induce the activation not
only of Th2 but also of Th0.
On the other hand, no apparent effect on IL-4, IL-10, and IFN-
activities was observed in the culture with IFN-
-primed
CD11c- DCs, in contrast to that with untreated
DCs (Fig. 5
). However, the counteracting effect of IFN-
on
IFN-
-induced-maturing CD11c+ DCs was also
evident when these were added simultaneously, and this was also the
case with CD11c- DCs stimulated with IL-3 (Figs. 5
and 7
), indicating that the effect of IFN-
on
CD11c- DCs is to modulate the T cell-stimulating
activity and T cell functions. IFN-
has been shown to inhibit
mitogen-induced IL-12 production in bulk PBMC in an IL-10-dependent
mechanism (27). In addition, IFN-
was demonstrated
to interfere with macrophage activation via a high affinity receptor
for IFN-
(17). Thus, the defeating action of IFN-
on
IFN-
-mediated stimulation may partly be ascribed to IL-10 produced
from DCs and activated T cells. However, the physiological mechanism of
the action of IFN-
on IL-3-mediated activation remains to be
elucidated. Using IFN-
, we have obtained results similar to those
for IFN-
(data not shown).
Recent progress has shown that myeloid DCs and lymphoid DCs can have
distinct roles in T cell-mediated immune responses (4);
monocyte-derived DCs (DC1) induce Th1 development, while DCs derived
from the plasmacytoid cells (DC2) preferentially induce Th2
development. In agreement with this, two types of DCs in the blood
without cytokine modification have the capacity to induce different Th
cell development, as shown in our present study. However,
monocyte-derived DCs treated with IL-10 or PGE2
can, in turn, induce Th2 development (28, 29). In
addition, virus-stimulated plasmacytoid DCs acquire the capacity to
induce IFN-
/IL-10-producing Th cells, but not Th2 cells
(26). We have additionally shown that 1) IFN-
enhances
CD11c+ DC-induced Th1 development, while IFN-
converts this and induces Tr; and 2) IL-3 promotes
CD11c- DC-induced Th2/Th0 development, while
IFN-
inhibits this T cell development. Thus, not only do DCs in the
different lineage have their own potential to induce respective Th
responses, but even DCs in the same lineage can induce different Th
responses depending on the signals or cytokine milieu involved in DC
maturation.
Based on these findings, the physiological actions of growth/maturation
factors such as GM-CSF, IL-3, and both types of IFNs on
CD11c+ and CD11c- DCs are
illustrated in Fig. 8
. GM-CSF mainly acts
on CD11c+ DCs as a factor to induce their
development and to maintain their survival, but not to induce
maturation in the tissue, whereas IL-3 not only sustains the survival
of CD11c- DCs, but also induces their
maturation. Once they encounter infection with virus, micro-organisms,
or parasites, CD11c+ DCs pick up the Ags, migrate
to the draining lymphoid organs, and induce T cell-mediated specific
immune responses to Th1 by other maturation-inducing factors, such as
IFN-
(shown in this study), or TNF-
, IL-1
, and CD40L
(30). On the other hand, CD11c- DCs
rapidly produce a remarkable amount of IFN-
, which stimulates
CD11c+ DC maturation to induce Tr and block
CD11c- DC maturation. Moreover, IFN-
intervenes in the effect of IFN-
on CD11c+ DCs
and that of IL-3 on CD11c- DCs, thereby
rendering them able to polarize T cells toward a Tr response and
reducing the Th2/Th0 response, respectively. The effects of IFN-
and IFN-
depend on their relative concentrations at the local
inflammatory sites and within the lymphoid tissues at the initiation
and effector phases of the immune response. It can be speculated that
IL-12-dependent Th1 response is down-regulated by Tr cells that
directly suppress the Th1 response and by Th2 cells that indirectly
modulate the differentiation of Th1. Moreover, IFN-
may act on
unprimed CD11c- DCs infiltrating inflammatory
lymphoid organs in a paracrine manner to arrest their further
maturation. This view seems compatible with the accumulation of
plasmacytoid T cells around high endothelial venules areas in inflamed
lymphoid tissues (31, 32, 33).
|

is an important factor in the
immune network as a negative regulatory element that limits
immunopathologic effects of prolonged exposure to Th1 cytokines. The
immunomodulatory effects of IFN-
on DC-mediated T cell responses
may also provide a novel mechanism for potential therapeutic benefits,
for instance in viral infections such as hepatitis B or C (34, 35) and autoimmune diseases (36, 37). In addition,
a recent report suggests that recipient DCs might play an important
role in the pathogenesis of graft-vs-host disease in allogeneic bone
marrow transplantation (38). Therefore, it is interesting
to know how IFN-
modulates the induction or severity of
graft-vs-host disease through its effects on DCs. In conclusion, distinctive DC subsets in human peripheral blood exhibit their own functions in the cytokine network, especially in the IFN milieu, resulting in the modulation of immune responses.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Tomoki Ito, First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi City, Osaka 570-8506, Japan. ![]()
3 Abbreviations used in this paper: DC, dendritic cell; sCD40L, soluble CD40 ligand. ![]()
Received for publication September 11, 2000. Accepted for publication December 13, 2000.
| References |
|---|
|
|
|---|
and
and prostaglandin E2. Proc. Natl. Acad. Sci. USA 85:6880.
increases the frequency of interferon
-producing human CD4+ T cells. J. Exp. Med. 178:1655.
production by natural killer cells and NK1.1+ T cells upon NKR-P1 cross-linking. J. Exp. Med. 183:2391.
production by CD8
+ lymphoid dendritic cells. J. Exp. Med. 189:1981.
and
on activation of human macrophages: two classes of interferon
receptors and blockade of the high-affinity sites by interferon
and
. J. Exp. Med. 167:1171.
-producing capacity in whole blood culture from patients with various diseases and from healthy persons. J. Interferon Cytokine Res. 16:911.[Medline]
and -
inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14+ precursors. Blood 96:210.
induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J. Immunol. 50:499.[Medline]
producing by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
/
-producing cells link innate and adaptive immunity. J. Exp. Med. 192:219.
-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-
-1b therapeutic effects in multiple sclerosis. J. Immunol. 165:548.
interferon. Lancet 338:914.
-2b (rhIFN
-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP). Am. J. Hematol. 51:37.[Medline]
This article has been cited by other articles:
![]() |
S. Ju, S. Ju, Y. Ge, H. Qiu, B. Lu, Y. Qiu, J. Fu, G. Liu, Q. Wang, Y. Hu, et al. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling Int. Immunol., October 1, 2009; 21(10): 1135 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hashimoto-Okada, T. Kitawaki, N. Kadowaki, S. Iwata, C. Morimoto, T. Hori, and T. Uchiyama The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4+ T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans Int. Immunol., August 1, 2009; 21(8): 891 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Longhi, C. Trumpfheller, J. Idoyaga, M. Caskey, I. Matos, C. Kluger, A. M. Salazar, M. Colonna, and R. M. Steinman Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant J. Exp. Med., July 6, 2009; 206(7): 1589 - 1602. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gerlini, G. Mariotti, A. Chiarugi, P. Di Gennaro, R. Caporale, A. Parenti, L. Cavone, A. Tun-Kyi, F. Prignano, R. Saccardi, et al. Induction of CD83+CD14+ Nondendritic Antigen-Presenting Cells by Exposure of Monocytes to IFN-{alpha} J. Immunol., September 1, 2008; 181(5): 2999 - 3008. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Li, B. Xu, S. A. Michie, K. H. Rubins, R. D. Schreriber, and H. O. McDevitt Interferon-{alpha} initiates type 1 diabetes in nonobese diabetic mice PNAS, August 26, 2008; 105(34): 12439 - 12444. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bochtler, A. Kroger, R. Schirmbeck, and J. Reimann Type I IFN-Induced, NKT Cell-Mediated Negative Control of CD8 T Cell Priming by Dendritic Cells J. Immunol., August 1, 2008; 181(3): 1633 - 1643. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Onishi, Z. Fehervari, T. Yamaguchi, and S. Sakaguchi Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation PNAS, July 22, 2008; 105(29): 10113 - 10118. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fiorentini, E. Riboldi, F. Facchetti, M. Avolio, M. Fabbri, G. Tosti, P. D. Becker, C. A. Guzman, S. Sozzani, and A. Caruso HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype PNAS, March 11, 2008; 105(10): 3867 - 3872. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Veckman and I. Julkunen Streptococcus pyogenes activates human plasmacytoid and myeloid dendritic cells J. Leukoc. Biol., February 1, 2008; 83(2): 296 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Frasca, M. Nasso, F. Spensieri, G. Fedele, R. Palazzo, F. Malavasi, and C. M. Ausiello IFN-{gamma} Arms Human Dendritic Cells to Perform Multiple Effector Functions J. Immunol., February 1, 2008; 180(3): 1471 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takahashi, S. Satoi, H. Yanagimoto, N. Terakawa, H. Toyokawa, T. Yamamoto, Y. Matsui, S. Takai, A-H. Kwon, and Y. Kamiyama Circulating Dendritic Cells and Development of Septic Complications After Pancreatectomy for Pancreatic Cancer Arch Surg, December 1, 2007; 142(12): 1151 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Kvale, Y. Floisand, F. Lund-Johansen, H. Rollag, L. Farkas, S. Ghanekar, P. Brandtzaeg, F. L. Jahnsen, and J. Olweus Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells Blood, April 15, 2007; 109(8): 3369 - 3376. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perreau, F. Mennechet, N. Serratrice, J. N. Glasgow, D. T. Curiel, H. Wodrich, and E. J. Kremer Contrasting Effects of Human, Canine, and Hybrid Adenovirus Vectors on the Phenotypical and Functional Maturation of Human Dendritic Cells: Implications for Clinical Efficacy J. Virol., April 1, 2007; 81(7): 3272 - 3284. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Cameron, A. J. Handley, D. C. Baylis, A. E. Solomon, N. Bernard, D. F. J. Purcell, and S. R. Lewin Preferential Infection of Dendritic Cells during Human Immunodeficiency Virus Type 1 Infection of Blood Leukocytes J. Virol., March 1, 2007; 81(5): 2297 - 2306. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schmidlin, W. Dontje, F. Groot, S. J. Ligthart, A. D. Colantonio, M. E. Oud, E. J. Schilder-Tol, M. Spaargaren, H. Spits, C. H. Uittenbogaart, et al. Stimulated plasmacytoid dendritic cells impair human T-cell development Blood, December 1, 2006; 108(12): 3792 - 3800. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dolganiuc, S. Chang, K. Kodys, P. Mandrekar, G. Bakis, M. Cormier, and G. Szabo Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-{alpha} and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection J. Immunol., November 15, 2006; 177(10): 6758 - 6768. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Romieu-Mourez, M. Solis, A. Nardin, D. Goubau, V. Baron-Bodo, R. Lin, B. Massie, M. Salcedo, and J. Hiscott Distinct Roles for IFN Regulatory Factor (IRF)-3 and IRF-7 in the Activation of Antitumor Properties of Human Macrophages Cancer Res., November 1, 2006; 66(21): 10576 - 10585. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Plskova, K. Greiner, E. Muckersie, L. Duncan, and J. V. Forrester Interferon-{alpha}: A Key Factor in Autoimmune Disease? Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3946 - 3950. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, Y.-H. Wang, O. Duramad, S. Hanabuchi, O. A. Perng, M. Gilliet, F. X.-F. Qin, and Y.-J. Liu OX40 ligand shuts down IL-10-producing regulatory T cells PNAS, August 29, 2006; 103(35): 13138 - 13143. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stasiolek, A. Bayas, N. Kruse, A. Wieczarkowiecz, K. V. Toyka, R. Gold, and K. Selmaj Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis Brain, May 1, 2006; 129(5): 1293 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Koelle, J. Huang, M. T. Hensel, and C. L. McClurkan Innate Immune Responses to Herpes Simplex Virus Type 2 Influence Skin Homing Molecule Expression by Memory CD4+ Lymphocytes J. Virol., March 15, 2006; 80(6): 2863 - 2872. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Kvale, J. Dalgaard, F. Lund-Johansen, H. Rollag, L. Farkas, K. Midtvedt, F. L. Jahnsen, J. E. Brinchmann, and J. Olweus CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection Blood, March 1, 2006; 107(5): 2022 - 2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chaperot, A. Blum, O. Manches, G. Lui, J. Angel, J.-P. Molens, and J. Plumas Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells J. Immunol., January 1, 2006; 176(1): 248 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tada, S. Aiba, K.-I. Shibata, T. Ohteki, and H. Takada Synergistic Effect of Nod1 and Nod2 Agonists with Toll-Like Receptor Agonists on Human Dendritic Cells To Generate Interleukin-12 and T Helper Type 1 Cells Infect. Immun., December 1, 2005; 73(12): 7967 - 7976. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Coleman, A. Clayton, M. D. Mason, B. Jasani, M. Adams, and Z. Tabi Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer Cancer Res., August 1, 2005; 65(15): 7000 - 7006. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Morita, T. Uchiyama, and T. Hori Nitric Oxide Inhibits IFN-{alpha} Production of Human Plasmacytoid Dendritic Cells Partly via a Guanosine 3',5'-Cyclic Monophosphate-Dependent Pathway J. Immunol., July 15, 2005; 175(2): 806 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Vlad, R. Cortesini, and N. Suciu-Foca License to Heal: Bidirectional Interaction of Antigen-Specific Regulatory T Cells and Tolerogenic APC J. Immunol., May 15, 2005; 174(10): 5907 - 5914. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tabata, N. Kadowaki, T. Kitawaki, T. Shimaoka, S. Yonehara, O. Yoshie, and T. Uchiyama Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells J. Leukoc. Biol., May 1, 2005; 77(5): 777 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hashizume, T. Horibe, H. Yagi, N. Seo, and M. Takigawa Compartmental Imbalance and Aberrant Immune Function of Blood CD123+ (Plasmacytoid) and CD11c+ (Myeloid) Dendritic Cells in Atopic Dermatitis J. Immunol., February 15, 2005; 174(4): 2396 - 2403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salek-Ardakani, S. A. Lyons, and J. R. Arrand Epstein-Barr Virus Promotes Human Monocyte Survival and Maturation through a Paracrine Induction of IFN-{alpha} J. Immunol., July 1, 2004; 173(1): 321 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Carbonneil, H. Saidi, V. Donkova-Petrini, and L. Weiss Dendritic cells generated in the presence of interferon-{alpha} stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells Int. Immunol., July 1, 2004; 16(7): 1037 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, R. Amakawa, M. Inaba, T. Hori, M. Ota, K. Nakamura, M. Takebayashi, M. Miyaji, T. Yoshimura, K. Inaba, et al. Plasmacytoid Dendritic Cells Regulate Th Cell Responses through OX40 Ligand and Type I IFNs J. Immunol., April 1, 2004; 172(7): 4253 - 4259. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kaser, S. Kaser, N. C. Kaneider, B. Enrich, C. J. Wiedermann, and H. Tilg Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression Blood, January 15, 2004; 103(2): 648 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nagai, O. Devergne, T. F. Mueller, D. L. Perkins, J. M. van Seventer, and G. A. van Seventer Timing of IFN-{beta} Exposure during Human Dendritic Cell Maturation and Naive Th Cell Stimulation Has Contrasting Effects on Th1 Subset Generation: A Role for IFN-{beta}-Mediated Regulation of IL-12 Family Cytokines and IL-18 in Naive Th Cell Differentiation J. Immunol., November 15, 2003; 171(10): 5233 - 5243. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pichyangkul, T. P. Endy, S. Kalayanarooj, A. Nisalak, K. Yongvanitchit, S. Green, A. L. Rothman, F. A. Ennis, and D. H. Libraty A Blunted Blood Plasmacytoid Dendritic Cell Response to an Acute Systemic Viral Infection Is Associated with Increased Disease Severity J. Immunol., November 15, 2003; 171(10): 5571 - 5578. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jefford, M. Schnurr, T. Toy, K.-A. Masterman, A. Shin, T. Beecroft, T. Y. Tai, K. Shortman, M. Shackleton, I. D. Davis, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli Blood, September 1, 2003; 102(5): 1753 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kerkmann, S. Rothenfusser, V. Hornung, A. Towarowski, M. Wagner, A. Sarris, T. Giese, S. Endres, and G. Hartmann Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells J. Immunol., May 1, 2003; 170(9): 4465 - 4474. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fong, M. Mengozzi, N. W. Abbey, B. G. Herndier, and E. G. Engleman Productive Infection of Plasmacytoid Dendritic Cells with Human Immunodeficiency Virus Type 1 Is Triggered by CD40 Ligation J. Virol., October 2, 2002; 76(21): 11033 - 11041. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Gauzzi, I. Canini, P. Eid, F. Belardelli, and S. Gessani Loss of Type I IFN Receptors and Impaired IFN Responsiveness During Terminal Maturation of Monocyte-Derived Human Dendritic Cells J. Immunol., September 15, 2002; 169(6): 3038 - 3045. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wirths, J. Reichert, F. Grunebach, and P. Brossart Activated CD8+ T Lymphocytes Induce Differentiation of Monocytes to Dendritic Cells and Restore the Stimulatory Capacity of Interleukin 10-treated Antigen-presenting Cells Cancer Res., September 1, 2002; 62(17): 5065 - 5068. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Ahn, Y. Lee, C. Jeon, S.-J. Lee, B.-H. Lee, K. D. Choi, and Y.-S. Bae Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis Blood, August 13, 2002; 100(5): 1742 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Comeau, A.-R. Van der Vuurst de Vries, C. R. Maliszewski, and L. Galibert CD123bright Plasmacytoid Predendritic Cells: Progenitors Undergoing Cell Fate Conversion? J. Immunol., July 1, 2002; 169(1): 75 - 83. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K. Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara Interferon-{alpha} and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets J. Exp. Med., June 3, 2002; 195(11): 1507 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Berger, D. Hanlon, D. Kanada, M. Dhodapkar, V. Lombillo, N. Wang, I. Christensen, G. Howe, J. Crouch, P. El-Fishawy, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells Blood, April 15, 2002; 99(8): 2929 - 2939. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ni, J. Capodici, G. Cannon, D. Communi, J.-M. Boeynaems, K. Kariko, and D. Weissman Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-alpha Secretion and Signaling through a Nucleotide Receptor J. Biol. Chem., April 5, 2002; 277(15): 12689 - 12696. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Padovan, G. C. Spagnoli, M. Ferrantini, and M. Heberer IFN-{alpha}2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells J. Leukoc. Biol., April 1, 2002; 71(4): 669 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Luft, P. Luetjens, H. Hochrein, T. Toy, K.-A. Masterman, M. Rizkalla, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky IFN-{alpha} enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells Int. Immunol., April 1, 2002; 14(4): 367 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Buelens, E. J. Bartholome, Z. Amraoui, M. Boutriaux, I. Salmon, K. Thielemans, F. Willems, and M. Goldman Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties Blood, February 1, 2002; 99(3): 993 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dzionek, Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Gunther, I. Johnston, A. Lanzavecchia, T. Nagasaka, et al. BDCA-2, a Novel Plasmacytoid Dendritic Cell-specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon {alpha}/{beta} Induction J. Exp. Med., December 17, 2001; 194(12): 1823 - 1834. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kato, Y. Takaue, and H. Wakasugi T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells J. Leukoc. Biol., December 1, 2001; 70(6): 941 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nakano, M. Yanagita, and M. D. Gunn Cd11c+B220+Gr-1+ Cells in Mouse Lymph Nodes and Spleen Display Characteristics of Plasmacytoid Dendritic Cells J. Exp. Med., October 15, 2001; 194(8): 1171 - 1178. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |